CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
about
Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone.Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.The emerging role of pharmacogenetics: implications for clinical psychiatry.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.Emerging strategies and applications of pharmacogenomicsEffect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.CYP2D6 genotyping in breast cancer patients by liquid chromatography-electrospray ionization mass spectrometry.Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry.
P2860
Q33168000-953B5B9C-5567-408F-B0EF-78C669F5B80BQ33597438-99523C45-770E-4A01-B219-F4DCA08078C8Q35837661-D1684AAE-FD37-4DD2-8413-5972625AC4DDQ35873687-E519F2C0-0797-49FC-B5CF-40A24F37F280Q35909573-CE69FAA2-16E2-41FF-9712-7BE8057856A9Q35988130-3CD1330E-9CB1-491E-80BB-6A07287C4A80Q37305262-143D62C3-80AA-45E9-B8B4-E396BB37BC2DQ40382805-085AA1E2-DB41-4EE2-804A-3F55391F0021Q42733745-3DE7D4E7-5230-4668-B757-738B067D4EF9Q46508948-072F4624-1A16-48C1-8F12-B517CF340704Q51482811-E58DEB08-D23F-45E9-B178-D7AEDE968F2AQ54346186-378E4018-92EF-4D94-AEE6-827D43BB8AFDQ54355038-E24117BE-E72A-439D-885C-986628DD7AA9Q54393163-AD83150C-5323-4089-B8E0-83106B74BC07
P2860
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
CYP2D6 genotyping as an altern ...... s in a clinical trial setting.
@en
type
label
CYP2D6 genotyping as an altern ...... s in a clinical trial setting.
@en
prefLabel
CYP2D6 genotyping as an altern ...... s in a clinical trial setting.
@en
P2093
P2860
P356
P1433
P1476
CYP2D6 genotyping as an altern ...... s in a clinical trial setting.
@en
P2093
B M Silber
D Friedman
J Brockmoller
J Richmond
P2860
P356
10.1208/PS020433
P577
2000-01-01T00:00:00Z